Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289265 | 0.91 | GABRG2 (0.32) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL18289298 | 0.85 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL18280673 | 0.83 | — | — | |
| SCHEMBL18280681 | 0.81 | KDM4E (0.31) | GABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL18289274 | 0.80 | — | — | |
| SCHEMBL28098733 | 0.80 | TGFBR1 (0.32) | — | |
| SCHEMBL28098566 | 0.79 | GABRA1 (0.30) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL18289228 | 0.76 | — | — | |
| SCHEMBL18289300 | 0.76 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL18289267 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102570-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-9586969-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-9586969-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-9586969-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| CN-105960402-A | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | GABRA1 1996/4885GABRG2 2555/4885GABRB3 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.